IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Lin et al.

Serial No.:

08/182,183

Group Art Unit No.: 1812

Filed:

May 23, 1994

Examiner: Marianne P. Allen

For:

GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR

Docket No.:

SYNE-225E

ATTORNEY'S STATEMENT PURSUANT TO 37 C.F.R. 1.821(f)

Assistant Commissioner of Patents Washington, D.C. 20231

Dear Sir:

I hereby state that the content of the paper and computer readable copies of the accompanying Sequence Listing are the same.

Respectfully submitted,

Daniel R. Curry

Attorney for Applicants Registration No.: 32,727 Phone: (805) 447-8102

Date: January 5, 1996

Date: Please send all future correspondence to:

U.S. Patent Operations/DRC M/S 10-1-B AMGEN INC. Amgen Center 1840 Dehavilland Drive Thousand Oaks, California 91320-1789

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner of Patents Washington, D.C. 20231, on the date appearing below.

January 5, 1996

ate

Nola J. Wyeth